Have a feature idea you'd love to see implemented?
Let us know!
TELO Telomir Pharmaceuticals Inc
Price (delayed)
$4.47
Market cap
$132.36M
P/E Ratio
N/A
Dividend/share
N/A
EPS
N/A
Enterprise value
$131.52M
We are a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for
Highlights
Telomir Pharmaceuticals's debt has plunged by 100% YoY
Telomir Pharmaceuticals's equity has shrunk by 80% YoY and by 72% QoQ
The quick ratio has plunged by 57% from the previous quarter
Key stats
What are the main financial stats of TELO
Market
Valuations
Earnings
Shares outstanding
29.61M
Market cap
$132.36M
Enterprise value
$131.52M
Price to earnings (P/E)
N/A
Price to book (P/B)
299.4
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$17.92M
EBITDA
-$17.92M
Free cash flow
-$5.55M
Per share
Balance sheet
Liquidity
EPS
N/A
Free cash flow per share
-$0.19
Book value per share
$0.01
Revenue per share
$0
TBVPS
$0.04
Total assets
$1.04M
Total liabilities
$599,911
Debt
$0
Equity
$442,074
Working capital
$442,074
Debt to equity
0
Current ratio
1.74
Quick ratio
1.61
Net debt/EBITDA
0.05
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-806.3%
Return on equity
-1,087.9%
Return on invested capital
-2,787.9%
Return on capital employed
-4,053.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TELO stock price
How has the Telomir Pharmaceuticals stock price performed over time
Intraday
6.43%
1 week
12.88%
1 month
3.23%
1 year
N/A
YTD
N/A
QTD
-30.37%
Financial performance
How have Telomir Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$10.48M
Net income
-$23.02M
Gross margin
N/A
Net margin
N/A
TELO's operating income has dropped by 93% since the previous quarter
The company's net income fell by 23% QoQ
Growth
What is Telomir Pharmaceuticals's growth rate over time
Valuation
What is Telomir Pharmaceuticals stock price valuation
P/E
N/A
P/B
299.4
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Telomir Pharmaceuticals's equity has shrunk by 80% YoY and by 72% QoQ
Efficiency
How efficient is Telomir Pharmaceuticals business performance
The return on assets has dropped by 69% since the previous quarter
The ROE has contracted by 48% from the previous quarter
Dividends
What is TELO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TELO.
Financial health
How did Telomir Pharmaceuticals financials performed over time
The total assets is 74% greater than the total liabilities
TELO's total liabilities has dropped by 81% year-on-year but it is up by 12% since the previous quarter
The total assets has dropped by 80% year-on-year and by 50% since the previous quarter
Telomir Pharmaceuticals's debt is 100% less than its equity
Telomir Pharmaceuticals's debt has plunged by 100% YoY
The company's debt to equity has shrunk by 100% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.